His Royal Highness The Duke of York Helps Launch UK-Based Pharmaceutical Company, ProStrakan, in the Uni...( NEW YORK Feb. 14 /- His Royal Hig...),Health

NEW YORK, Feb. 14 /PRNewswire/ -- His Royal Highness, The Duke of York, was the guest of honour today at a lunch held to mark the United States launch of UK-based specialty pharmaceutical company, ProStrakan Group plc (LSE: PSK). ProStrakan's first US product, Sancuso, is currently under consideration for licensing by the US Food & Drug Administration.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080214/NYTH111 )

Prince Andrew is visiting the United States as the UK's Special Representative for International Trade & Investment. He accepted the invitation to today's lunch after visiting ProStrakan's headquarters in Galashiels, Scotland, last year at which time he was briefed on ProStrakan's plans for expansion into the US.

Commenting on today's visit, The Duke of York said:

"It gives me great pleasure to see ProStrakan establish itself in the United States. I was hugely impressed by the company's ambition and drive when I visited their headquarters in Galashiels last year. I am committed to doing everything I can to help UK companies like ProStrakan expand still further into the global marketplace."

ProStrakan's Chief Executive Officer, Dr Wilson Totten, the host of the lunch, said:

"ProStrakan was founded on a commitment to developing innovative products to meet the needs of patients. With that, we are pleased to announce our US business and today's event has marked our arrival here in the best possible way.

"We were delighted when Prince Andrew visited us in Galashiels last year but to have him join us as guest of honour today here in New York was a special privilege."

Also attending today's lunch were guests representing ProStrakan's US business partners, including Ron Wooten, Executive Vice President of Quintiles Transnational and President of NovaQuest; Patrick Jordan, Vice President of NovaQuest; and advisors and staff
'/>"/>